LinXis Fibrobodies center stage at World Molecular Imaging Congress

At the WIMC, Vedangi Kulkarni proudly presented key results obtained in the collaboration between LinXis, the LaBooratory of Aachen University Hospital (the expert lab on kidney fibrosis led by Professor Peter Boor), and Professor Twan Lammers' group of the Institute for Molecular Imaging. The results were presented by Professor Peter Caravan as a congress highlight during the plenary innovation showcase.

Together with Barbara Klinkhammer and Tim Caspers, Vedangi applied a non-invasive imaging approach to demonstrate convincing and selective accumulation of our Fibrobody-Tracer conjugate in the fibrotic kidney.

LinXis's Fibrobody is directed against PDGFRB. Previous work by Professor Boor already demonstrated that this fibroblast receptor plays a pivotal role in development of kidney fibrosis. Now, Vedangi's results demonstrate that it also is a valid target for non-invasive detection of kidney fibrosis.

As the Fibrobody can be functionalized not only for diagnostic-, but also for therapeutic purpose, the presented results fully underscore the potential of Fibrobody-based theranostics for diagnosis and treatment of fibrotic disease.